search
Back to results

Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis (OPTION)

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NEM
Placebo
Sponsored by
ESM Technologies, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Osteoarthritis focused on measuring osteoarthritis, arthritis, knee, eggshell, membrane, OPTION

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • known symptomatic osteoarthritis of the knee
  • patients must have been diagnosed with functional Grades I-III of osteoarthritis according to the modified criteria of the American College of Rheumatology
  • must also have had persistent knee pain associated with osteoarthritis with a baseline score of at least 30 mm on the Patient's Assessment of Arthritis Pain - Visual Analog Scale
  • required to suspend all current pain relief medications. Subjects that were currently taking analgesic medications were eligible to participate in the study following a 14 day washout period for NSAIDs, a 7 day washout for narcotics, and a 90 day washout for injected steroids. Subjects currently taking glucosamine, chondroitin sulfate or MSM were only eligible after a 3-month washout period.

Exclusion Criteria:

  • are currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months
  • had a confounding inflammatory disease or condition (rheumatoid arthritis, gout, pseudo gout, Paget's disease, chronic pain syndrome, etc.) that would interfere with assessment of pain associated with the index knee
  • body weight 250 pounds or greater
  • having a known allergy to eggs or egg products
  • pregnant or breastfeeding women
  • Subjects previously enrolled in a study to evaluate pain relief within the past 6 months or currently involved in any other research study involving an investigational product (drug, device, or biologic) or a new application of an approved product, within 30 days of screening

Sites / Locations

  • Regional Specialty Clinic
  • Regional Specialty Clinic
  • St. John's Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

NEM Treatment

Placebo

Arm Description

NEM, 500 mg, once daily, orally for 8 weeks

Placebo, 500 mg, once daily, orally for 8 weeks

Outcomes

Primary Outcome Measures

The primary endpoint of the study was measurement of the effectiveness of NEM® in relieving pain, stiffness, and discomfort associated with moderate OA of the knee and to compare its effectiveness to placebo.

Secondary Outcome Measures

Secondary objectives of the study were to evaluate tolerability and any adverse reactions associated with supplementation with NEM®.

Full Information

First Posted
September 8, 2008
Last Updated
February 11, 2016
Sponsor
ESM Technologies, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00750477
Brief Title
Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis
Acronym
OPTION
Official Title
A Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of Natural Eggshell Membrane (NEM) in the Treatment of Pain & Stiffness Associated With Moderate Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
December 2004 (undefined)
Primary Completion Date
January 2006 (Actual)
Study Completion Date
May 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ESM Technologies, LLC

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effectiveness of Natural Eggshell Membrane (NEM) for the relief of pain and stiffness associated with moderate osteoarthritis of the knee and to compare the effectiveness of NEM to placebo.
Detailed Description
Osteoarthritis (OA) is the most prevalent form of arthritis and is estimated to affect nearly 27 million adults in the U.S., with one third of those 65 and older having been diagnosed with OA. As the population ages, this estimate is expected to grow rapidly. Traditional treatments for OA primarily attempt to address the symptoms (pain, inflammation, and discomfort) associated with the disease. This usually involves the use of analgesics (i.e. acetaminophen, tramadol), non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. ibuprofen, diclofenac), or cyclooxygenase-2-specific (COX-2) NSAIDs (i.e. celecoxib) alone or in combination. Steroid and hyaluronic acid injections have also been used with some success. Many of these treatments have shown limited effectiveness in randomized controlled clinical trials (RCTs). To avoid the cardiac risks and gastrointestinal issues associated with traditional OA treatments (particularly with long-term use), many patients have turned to complementary and alternative medicines (CAMs) such as dietary supplements. The discovery of eggshell membrane as a natural source of combined glucosamine, chondroitin, and hyaluronic acid has prompted the evaluation of this material as a potential treatment for OA. ESM Technologies, LLC (Carthage, MO) has developed methods to efficiently and effectively separate eggshell membrane from eggshells to create a shell-free eggshell membrane. The isolated membrane is then partially hydrolyzed using a proprietary process and dry-blended to produce 100% pure Natural Eggshell Membrane (NEM®). In preliminary open-label human clinical trials totaling 37 subjects with OA, oral supplementation with 500 mg per day of NEM® resulted in an observed decrease in pain in 7-30 days. Therefore, an eight week randomized, multicenter, double blind, placebo controlled supplementation trial was conducted to evaluate the efficacy and safety of NEM® for the relief of the pain and stiffness associated with moderate OA of the knee - the Osteoarthritis Pain Treatment IncorpOrating NEM® (OPTION) trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
osteoarthritis, arthritis, knee, eggshell, membrane, OPTION

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
67 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NEM Treatment
Arm Type
Experimental
Arm Description
NEM, 500 mg, once daily, orally for 8 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, 500 mg, once daily, orally for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
NEM
Other Intervention Name(s)
Natural Eggshell Membrane
Intervention Description
see Treatment Arms
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo comparator containing inactives
Primary Outcome Measure Information:
Title
The primary endpoint of the study was measurement of the effectiveness of NEM® in relieving pain, stiffness, and discomfort associated with moderate OA of the knee and to compare its effectiveness to placebo.
Time Frame
10, 30, & 60 Days
Secondary Outcome Measure Information:
Title
Secondary objectives of the study were to evaluate tolerability and any adverse reactions associated with supplementation with NEM®.
Time Frame
10, 30, & 60 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: known symptomatic osteoarthritis of the knee patients must have been diagnosed with functional Grades I-III of osteoarthritis according to the modified criteria of the American College of Rheumatology must also have had persistent knee pain associated with osteoarthritis with a baseline score of at least 30 mm on the Patient's Assessment of Arthritis Pain - Visual Analog Scale required to suspend all current pain relief medications. Subjects that were currently taking analgesic medications were eligible to participate in the study following a 14 day washout period for NSAIDs, a 7 day washout for narcotics, and a 90 day washout for injected steroids. Subjects currently taking glucosamine, chondroitin sulfate or MSM were only eligible after a 3-month washout period. Exclusion Criteria: are currently receiving remission-inducing drugs such as methotrexate or immunosuppressive medications or had received them within the past 3 months had a confounding inflammatory disease or condition (rheumatoid arthritis, gout, pseudo gout, Paget's disease, chronic pain syndrome, etc.) that would interfere with assessment of pain associated with the index knee body weight 250 pounds or greater having a known allergy to eggs or egg products pregnant or breastfeeding women Subjects previously enrolled in a study to evaluate pain relief within the past 6 months or currently involved in any other research study involving an investigational product (drug, device, or biologic) or a new application of an approved product, within 30 days of screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Winkler, MD, PhD
Organizational Affiliation
St. John's Clinic - Rheumatology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert W Jackson, DO
Organizational Affiliation
Regional Specialty Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kevin J Ruff, PhD, MBA
Organizational Affiliation
ESM Technologies, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Regional Specialty Clinic
City
Cuba
State/Province
Missouri
ZIP/Postal Code
65453
Country
United States
Facility Name
Regional Specialty Clinic
City
Kirksville
State/Province
Missouri
ZIP/Postal Code
63501
Country
United States
Facility Name
St. John's Clinic
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65807
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19340512
Citation
Ruff KJ, Winkler A, Jackson RW, DeVore DP, Ritz BW. Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. Clin Rheumatol. 2009 Aug;28(8):907-14. doi: 10.1007/s10067-009-1173-4. Epub 2009 Apr 2.
Results Reference
result
Links:
URL
http://dx.doi.org/10.1007/s10067-009-1173-4
Description
Digital Object Identifier link to published study in Clinical Rheumatology.

Learn more about this trial

Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis

We'll reach out to this number within 24 hrs